DUSP6 and neoplasm: In vivo, administration of the DUSP1/DUSP6 inhibitor BCI increased ERK1/2 and JNK activation, caused tumour necrosis and fibrosis, and reduced tumour volume in MPNST xenografts established with S462.TY cells or patient-derived cells [38].